Description: NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Home Page: www.nervgen.com
112-970 Burrard Street
Vancouver,
BC
V6Z 2R4
Canada
Phone:
778 731 1711
Officers
| Name | Title |
|---|---|
| Mr. Michael Kelly | CEO, President & Director |
| Mr. William Joseph Radvak BASc | Co-Founder & Advisor |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director |
| Mr. William J. Adams C.A., CPA, CA, CPA | CFO & Corporate Secretary |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer |
| Mr. Brian McAlister | Co-Founder & Advisor |
| Dr. Charles V. Olson D.Sc. | Senior Vice President of Technical Operations |
| Ms. Elizabeth Eberhardt B.Sc. | Senior Vice President of Program Management |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 20.6964 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |